Power Law company profile

Glaukos

Biotech & Life Sciences · Aliso Viejo, United States · Founded 1998 · IPO 2015 Unicorn

Breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness

Valuation

$8.23B

Market cap · May/2026

Revenue

$507M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

11 investors on Glaukos's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage

Prism Venture Management

Versant Ventures

Borealis Ventures

Domain Associates

DeNovo Ventures

Frazier Healthcare Partners

Series B+ 5 investors entered at this stage

InterWest Partners

OrbiMed

Fjord Ventures

Meritech Capital

Montreux Equity Partners

Glaukos mafia

Startups founded by Glaukos alumni

Former Glaukos employees who went on to start their own companies. Sorted by Dealroom signal score.

Sionna TherapeuticsEst. 2019

Joshua ResnickUnited States

Signal score92

Nalu MedicalEst. 2014

Mike PartschUnited States

Signal score83

InariEst. 2016

David BerryUnited States

Signal score74

Remedium bioEst. 2020

Alex GoraltchoukUnited States

Signal score74

CloraEst. 2016

Rahul ChaturvediUnited States

Signal score72

VentriJectEst. 2018

Stig Visti AndersenDenmark

Signal score56

InveniasEst. 2005

Richard HarrisonUnited Kingdom

Signal score52

Book a demo to explore the full alumni network →

Global footprint

Where Glaukos has talent and traffic

AI talent share

0.1% of workforce is AI talent
(1 of 1,062 staff)

Core AI00%

Other AI10.09%

Non-AI workforce1,06199.91%

Workforce by country

23 countries with
team presence

🇺🇸 United States83.7%

🇩🇪 Germany2.8%

🇬🇧 United Kingdom2%

🇧🇷 Brazil1.7%

🇦🇺 Australia1.4%

Top 5 of 23 shown

Web traffic by country

16K monthly visits
across markets

🇺🇸 United States40%

🇯🇵 Japan16.9%

🇮🇳 India12.5%

🇨🇦 Canada10%

🇫🇷 France8.8%

Top 5 markets shown

Patent intelligence

$143M patent portfolio · 127 active families

Estimated portfolio value

$143M

1.7% of market cap · 6.5× smaller than top peer Globus Medical ($930M)

127 active patent families

Where Glaukos innovates OptometryOcular implantBiomedical engineeringOphthalmologyCornea

Where Glaukos concentrates vs peers

Each axis is a top-10 topic across Glaukos and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Glaukos

An AI-synthesized read of the highest-engagement posts about Glaukos on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Glaukos on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles